VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Toms on Targeting MEK as a Treatment Strategy for CNS Metastasis

Steven A. Toms, MD
Published: Friday, Nov 14, 2014

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastases.

Toms says he and his colleagues have been taking primary metastases cell lines out of bone and brain and analyzing them for genetic and epigenetic changes. The study showed that the MEK pathway was altered in a number of brain metastases, Toms says. These pathways are commonly deregulated in a wide variety of cancers.

Toms says this discovery may help researchers select specific targeted therapies to work on for treatment for these metastases. However, researchers might find that the cancer may be able to bypass the one pathway that is being inhibited. In order to combat that, Toms says, targeted therapies may need to be used in combination when targeting the MEK pathway.

<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastases.

Toms says he and his colleagues have been taking primary metastases cell lines out of bone and brain and analyzing them for genetic and epigenetic changes. The study showed that the MEK pathway was altered in a number of brain metastases, Toms says. These pathways are commonly deregulated in a wide variety of cancers.

Toms says this discovery may help researchers select specific targeted therapies to work on for treatment for these metastases. However, researchers might find that the cancer may be able to bypass the one pathway that is being inhibited. In order to combat that, Toms says, targeted therapies may need to be used in combination when targeting the MEK pathway.

<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x